NASDAQ:AURA Aura Biosciences (AURA) Stock Price, News & Analysis $6.03 -0.11 (-1.79%) Closing price 04:00 PM EasternExtended Trading$6.03 0.00 (0.00%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Aura Biosciences Stock (NASDAQ:AURA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Aura Biosciences alerts:Sign Up Key Stats Today's Range$5.88▼$6.1650-Day Range$6.00▼$7.9052-Week Range$4.73▼$9.53Volume746,585 shsAverage Volume929,850 shsMarket Capitalization$625.37 millionP/E RatioN/ADividend YieldN/APrice Target$17.50Consensus RatingHold Company Overview Aura Biosciences, Inc. (NASDAQ:AURA) is a clinical-stage biotechnology company developing targeted therapies for cancer. The company’s platform is designed to use tumor-targeting virus-like particles to selectively bind to cancer cells and deliver therapeutic payloads, with the goal of treating tumors while limiting damage to surrounding healthy tissue. Aura’s lead product candidate is AU-011, also known as belzupacap sarotalocan, an investigational therapy being developed for primary choroidal melanoma, a form of eye cancer. AU-011 is administered by intravitreal injection and is designed to target tumor cells in the eye before activating a light-based treatment intended to destroy them. The company is also advancing additional candidates based on its tumor-targeting technology for other solid tumors. Founded in 2009 and headquartered in the United States, Aura Biosciences conducts research and clinical development activities through collaborations and clinical programs in the U.S. and other regions. The company was founded and is led by Elisabet de los Pinos, who serves as president and chief executive officer.AI Generated. May Contain Errors. Read More Aura Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks45th Percentile Overall ScoreAURA MarketRank™: 2.24908759124 of 5 starsAura Biosciences scored higher than 45% of companies evaluated by MarketBeat, and ranked 636th out of 894 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingHold Consensus RatingAura Biosciences has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on no strong buy ratings, 2 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialAura Biosciences has a consensus price target of $17.50, representing about 190.2% upside from its current price of $6.03.Amount of Analyst CoverageAura Biosciences has only been the subject of 2 research reports in the past 90 days.Read more about Aura Biosciences' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Aura Biosciences are expected to grow in the coming year, from ($1.61) to ($1.39) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aura Biosciences is -3.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aura Biosciences is -3.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAura Biosciences has a P/B Ratio of 2.79. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Aura Biosciences' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted10.70% of the float of Aura Biosciences has been sold short.Short Interest Ratio / Days to CoverAura Biosciences has a short interest ratio ("days to cover") of 10.63, which indicates bearish sentiment.Change versus previous monthShort interest in Aura Biosciences has recently increased by 5.01%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAura Biosciences does not currently pay a dividend.Dividend GrowthAura Biosciences does not have a long track record of dividend growth. News and Social Media4.2 / 5News Sentiment0.77 News SentimentAura Biosciences has a news sentiment score of 0.77. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.67 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Aura Biosciences this week, compared to 3 articles on an average week.Search Interest2 people have searched for AURA on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows1 people have added Aura Biosciences to their MarketBeat watchlist in the last 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Aura Biosciences insiders have not sold or bought any company stock.Percentage Held by Insiders1.90% of the stock of Aura Biosciences is held by insiders.Percentage Held by Institutions96.75% of the stock of Aura Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Aura Biosciences' insider trading history. Receive AURA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aura Biosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AURA Stock News HeadlinesAura Biosciences: A Pivotal Trial Engineered With Room To SpareOctober 31 at 8:00 AM | seekingalpha.comAura Biosciences (NASDAQ:AURA) Stock Jumps 1.6% - Here's What HappenedOctober 29, 2026 | americanbankingnews.comGovernment Document Reveals Plan To Control Your Money (it will disturb you)A Federal Reserve filing, Docket No. OP-1670, is drawing scrutiny for language that could expand the Fed's visibility into consumer bank transactions. A pilot program is reportedly already underway, with wider rollout at major banks possibly beginning this summer. Martin D. Weiss, PhD, founder of Weiss Ratings, breaks down what the document says and what steps account holders might consider.November 2 at 1:00 AM | Weiss Ratings (Ad)Aura Biosciences, Inc.(NasdaqGM:AURA) added to S&P Biotechnology Select Industry IndexSeptember 21, 2026 | marketscreener.comMAura Biosciences, Inc. (AURA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeptember 16, 2026 | seekingalpha.comAura Biosciences to Participate in Upcoming Investor ConferenceSeptember 2, 2026 | globenewswire.comAura Biosciences Grants Inducement Equity Awards to Newly Appointed ExecutivesSeptember 1, 2026 | quiverquant.comQAura Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)September 1, 2026 | globenewswire.comSee More Headlines AURA Stock Analysis - Frequently Asked Questions How have AURA shares performed this year? Aura Biosciences' stock was trading at $5.45 at the start of the year. Since then, AURA stock has increased by 10.6% and is now trading at $6.03. How were Aura Biosciences' earnings last quarter? Aura Biosciences, Inc. (NASDAQ:AURA) announced its earnings results on Tuesday, August, 11th. The company reported ($0.48) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.38) by $0.11. When did Aura Biosciences IPO? Aura Biosciences (AURA) raised $81 million in an initial public offering on Thursday, October 28th 2021. The company issued 5,400,000 shares at a price of $14.00-$16.00 per share. Who are Aura Biosciences' major shareholders? Top institutional investors of Aura Biosciences include China Universal Asset Management Co. Ltd. (0.03%), Profund Advisors LLC (0.01%), ProShare Advisors LLC (0.01%) and Mirae Asset Global Investments Co. Ltd. (0.01%). Insiders that own company stock include Los Pinos Elisabet De, Anthony S Gibney, Janet Jill Hopkins, Conor Kilroy, Mark Plavsic, David Michael Johnson, Julie B Feder, Amy Elazzouzi and Matrix Capital Management Comp. View institutional ownership trends. How do I buy shares of Aura Biosciences? Shares of AURA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Aura Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Aura Biosciences investors own include Micron Technology (MU), Palantir Technologies (PLTR), SoFi Technologies (SOFI), NVIDIA (NVDA), Advanced Micro Devices (AMD), Applied Digital (APLD) and Aurora Innovation (AUR). Company Calendar Last Earnings8/11/2026Today11/02/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1w+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 For the last 10 days, AURA's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:AURA CIK1501796 Webwww.aurabiosciences.com Phone617-500-8864FaxN/AEmployees113Year Founded2009Price Target and Rating Average Price Target for Aura Biosciences$17.50 High Price Target$18.00 Low Price Target$17.00 Potential Upside/Downside+190.2%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($1.75) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$106.19 million Net MarginsN/A Pretax MarginN/A Return on Equity-73.18% Return on Assets-62.00% Debt Debt-to-Equity RatioN/A Current Ratio16.82 Quick Ratio16.82 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.16 per share Price / Book2.79Miscellaneous Outstanding Shares103,710,000Free Float101,735,000Market Cap$625.37 million OptionableOptionable Beta0.41 Social Links Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NASDAQ:AURA) was last updated on 11/2/2026 by MarketBeat.com Staff. From Our PartnersI'm handing you this one freeElon Musk doesn't own the chip powering every Tesla, every Starlink dish, and every AI satellite he builds, he...Behind the Markets | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredNEVER thought this would happen againTwenty five years ago, this analyst predicted the fiber optic boom and called Amazon before it became a househ...Porter & Company | SponsoredElon Musk about to bankrupt Amazon, Microsoft & Google?Jeff Brown, the former tech executive who called the rise of Bitcoin, Tesla, and Nvidia years early, is tracki...Brownstone Research | SponsoredLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, p...Profits Run | SponsoredTrump’s issues shocking Executive Order on U.S. DollarThree days into his second term, President Trump signed Executive Order 14178 a move the press barely covered....Banyan Hill Publishing | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | SponsoredDoes your nest egg have an expiration date?A $250,000 nest egg growing at 5% a year and paying out $2,500 a month runs dry in just over a decade. Start w...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aura Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aura Biosciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
